George Millen: Unscripted

Copper Quest diversifies from copper, acquiring a high-grade gold mine and adding 150+ years of mining expertise to its board and advisory team.

Impressive new trial data for MDNA11 could disrupt the multi-billion dollar immunotherapy market, offering real hope where standard treatments now fail.

Exodus is using its Bitcoin treasury to buy a payments firm, but declining user metrics and a change in disclosure raise questions about this bold strategy.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

Groundbreaking lymphoma data and a strategic acquisition position Natera to dominate the liquid biopsy market, challenging old standards and creating new value.

Facing an OSC probe and audit delays, the legal tech firm is now seeking court relief, raising red flags for investors about its governance and finances.

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

With its CFO departing after a major strategic pivot, AAR CORP. names a 13-year insider as his interim replacement. What does this signal for investors?

The battery innovator secures fresh capital to scale its 'One-Pot' process. We analyze if this move signals a turning point for investors and the EV market.

Tile Shop is delisting from Nasdaq, forcing a cash-out for small investors. We analyze the high-stakes maneuver to save millions and what it signals.

A landmark deal creates Canada's largest private brokerage. We analyze the PE-backed strategy, the 'Canadian Champion' gambit, and what it means for the market.

LAMY's all-stock deal for Exousia AI is more than a merger; it's a strategic coup built on an early FDA designation for a novel brain cancer therapy.

Gelteq is pitching its innovative drug delivery gel to investors. But with a 'going concern' warning, can its promising tech secure the cash it needs to survive?

NextNRG's landmark FIU deal showcases next-gen EV charging, but can this high-stakes tech validation project power the company past its financial woes?

A breakthrough in Nevada could let Century Lithium produce both lithium and rare earths, reshaping its financial future and the North American supply chain.

GlobalTech Corp. acquires a majority stake in Moda in Pelle, aiming to inject its AI into the premium footwear market. A bold move or a risky bet?

Urbanfund Corp. just unlocked over $8M in capital by refinancing a Toronto asset. Here's what this savvy move signals about its growth plans and the market.

How did Pollard Banknote's subsidiary lock in a key Colorado Lottery contract? A 17% sales boost from digital tech proved its value.

Cadrenal Therapeutics appoints Dr. Lee Golden to its board, a strategic move signaling a push to accelerate its pipeline in a competitive market.

As ProQR prepares for its Evercore chat, investors weigh the promise of its unique RNA editing platform against a field of biotech giants.